Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
5.18
+0.64 (14.10%)
At close: Dec 20, 2024, 4:00 PM
5.44
+0.26 (5.02%)
After-hours: Dec 20, 2024, 7:22 PM EST
Telomir Pharmaceuticals Employees
As of December 31, 2023, Telomir Pharmaceuticals had 9 total employees, including 1 full-time and 8 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,551,284
Market Cap
153.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Nevro | 1,215 |
| The Joint | 794 |
| Adaptimmune Therapeutics | 449 |
| Sutro Biopharma | 302 |
| Metagenomi | 236 |
| Seres Therapeutics | 233 |
| Cellectis | 221 |
| Biomea Fusion | 103 |
TELO News
- 9 days ago - Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - Accesswire
- 18 days ago - Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday? - Benzinga
- 18 days ago - Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 - Accesswire
- 4 weeks ago - Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 - Accesswire
- 3 months ago - Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday - Accesswire
- 3 months ago - Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications - Accesswire
- 4 months ago - Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs - Accesswire
- 4 months ago - Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman - GlobeNewsWire